In Nepal, a community based trial showed that chlorhexidine use was associated with a 24% nonsignificant reduction (95% CI 0.55-1.04) ineonatalal mortality compared to dry cord-care; among infants enrolled within the first 24 hours, mortality was significantly lower in the intervention group (RR 0.66; 95% CI 0.46-0.95) [ 271].
Our experience conducting a step-wedge cluster-randomised community-based trial shows that the application of such studies is feasible to evaluate complex health interventions, even when working in resource-limited settings, and provides a unique opportunity to produce sound evidence for decision-making in health policy.
In conclusion, our pilot trial shows that a community based intervention using locally available resources is feasible, acceptable and leads to significant improvements in caregiver mental health and burden of caring and is associated with reduced mortality of the person with dementia.
Our economic model, which was based on data from the RESTORE clinical trial, shows that ranibizumab monotherapy provides superior improvements in visual acuity and is cost-effective relative to the current standard of care, laser photocoagulation.
This randomised controlled trial shows that a highly structured and very short parent based language intervention group programme is effective.
25 With the exception of one large, UK based trial that showed little effect of cardiac rehabilitation on mortality at two years (relative risk 0.98 (0.74 to 1.30)), 26 findings from meta-analyses and observational studies support a mortality benefit.
But the statistician's report on which it was based, produced at the trial, showed that the weight loss was not significant, or only marginally so.
A mathematical modelling study based on data from the iPrEx trial showed that protection from HIV infection may be correlated with a specific number of PrEP doses per week, regardless of exact dosing intervals [ 24].
Consistent findings from a randomized controlled trial showed that mindfulness based interventions improved depression and HRQOL at six months follow up in people with MS, while control subjects had a worsening of symptoms [ 12, 74].
Sepracor, which is based in Marlborough, Mass., sponsored a clinical trial showing that its drug, Estorra, worked for six months without loss of effectiveness, providing about 35 minutes more sleep per night than a placebo.
When testimony in the embassy bombings trial showed that three men had based their surveillance of the American Embassy in Kenya from an improvised darkroom in a cramped Nairobi apartment, it sounded like something taken from a manual called Terrorism 101.
